53,352 results match your criteria: "MD Anderson Cancer Center[Affiliation]"
Biophys J
December 2024
Program in Integrative Nutrition & Complex Diseases, Texas A&M University, College Station, TX 77843, USA,; Department of Nutrition, Texas A&M University, College Station, TX 77843, USA,; CPRIT Regional Center of Excellence in Cancer Research, Texas A&M University, College Station, TX 77843, USA,. Electronic address:
Cholesterol-enriched plasma membrane domains are known to serve as signaling platforms in a diverse array of cellular processes. However, the link between cholesterol homeostasis and mutant APC-KRas-associated colorectal tumorigenesis remains to be established. Thus, we investigated the impact of Apc-Kras on (i) colonocyte plasma membrane cholesterol homeostasis, order, and receptor nanoclustering, (ii) colonocyte cell proliferation, and (iii) whether these effects are modulated by select membrane active dietaries (MADs).
View Article and Find Full Text PDFHereditas
December 2024
Facultad de Ciencias Biológicas, Departamento de Biología Celular y Genética, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México.
Background: Breast cancer is the most prevalent cancer among women worldwide. Most breast cancer-related deaths result from metastasis and drug resistance. Novel therapies are imperative for targeting metastatic and drug-resistant breast cancer cells.
View Article and Find Full Text PDFEur Urol Oncol
December 2024
Helen Diller Family Cancer Center, University of California-San Francisco, San Francisco, CA, USA. Electronic address:
Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data available. Outcomes for groups with and without a particular biomarker were compared using logistic regression (unadjusted) for the objective response rate (ORR), and a log-rank test and Cox proportional-hazard models (CPHMs) for progression-free survival (PFS) and overall survival (OS) from EV initiation.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
November 2024
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:
Background: The prognosis of multiple myeloma involving the central nervous system (CNS-MM) is poor. We report outcomes of CNS-MM treated with CNS-directed radiation therapy (RT).
Methods: We retrospectively reviewed patients with CNS-MM treated with CNS-directed RT from 2015 to 2024.
Hum Pathol
December 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address:
Flow cytometry immunophenotypic analysis is an important and indispensable tool in the diagnosis of mature B-cell lymphomas/leukemias, particularly for small fine needle aspiration and needle core biopsy specimens which are becoming increasingly popular for diagnostic purposes. Flow cytometry immunophenotyping (FCI) has several advantages. Given its multiparametric nature, FCI can analyze the expression of multiple antigens simultaneously on the same cell of interest, qualitatively and quantitively.
View Article and Find Full Text PDFAnn Thorac Surg
December 2024
Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, 1400 Pressler St, Unit 1489, Houston, Texas 77030. Electronic address:
Eur J Gastroenterol Hepatol
February 2025
Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Clin Lung Cancer
November 2024
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. Electronic address:
Background: With increased early detection efforts, surgery for early-stage lung cancer is expected to rise. Pafolacianine is the first FDA approved targeted optical imaging agent indicated as an adjunct for intraoperative identification of malignant and nonmalignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
Methods: This is a retrospective review of the malignant and nonmalignant lesions identified by pafolacianine with intraoperative molecular imaging (IMI) in the multi-center Phase 2 and Phase 3 ELUCIDATE clinical trials.
Ann Thorac Surg
December 2024
Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, 1400 Pressler St, Unit 1489, Houston, Texas 77030. Electronic address:
Ann Thorac Surg
December 2024
Ascension Saint Thomas Hospital, University of Tennessee Health Science Center, Division of Thoracic Surgery, Nashville, TN.
Objective: With robotic technology's rapid growth and integration, an urgent need to bridge the educational gap in thoracic surgical training has emerged. This document, a result of consensus among a group of experts in the practice and training of robotic surgery from the Society of Thoracic Surgeons (STS), aims to provide a framework for a standardized national robotic curriculum for thoracic surgery trainees.
Methods: The STS Task Force on Robotic Thoracic Surgery and Workforce on E-learning and Educational Innovation assembled an expert group with the input of the Thoracic Surgery Director's Association (TSDA).
J Am Coll Radiol
December 2024
Department of Interventional Radiology: The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens Academic Tower, Houston, TX 77030-4000. Electronic address:
Objective: To evaluate the relevance of established surgical risk calculators (SRCs) for predicting complications in patients undergoing percutaneous lung cryoablation (PLC).
Methods: The institution's database was queried for PLC procedures from March 2015 to May 2024, excluding those patients with concomitant local therapies or five or more lesions treated in a single setting. Demographics, frailty metrics as defined by the surgical literature, and procedural variables were collected.
Ann Oncol
December 2024
Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Background: Fibroblast growth factor receptor (FGFR) inhibitors have significantly improved outcomes for patients with FGFR-altered cholangiocarcinoma, leading to their regulatory approval in multiple countries. However, as with many targeted therapies, acquired resistance limits their efficacy. A comprehensive, multimodal approach is crucial to characterizing resistance patterns to FGFR inhibitors.
View Article and Find Full Text PDFAnn Oncol
December 2024
Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:
Background: In the phase 3 JAVELIN Renal 101 trial (NCT02684006), first-line treatment with avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib in patients with advanced renal cell carcinoma (aRCC). We report the final analysis, including the primary analysis of overall survival (OS).
Patients And Methods: Patients with untreated aRCC (any prognostic risk score) were enrolled.
J Gastrointest Surg
December 2024
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY; Departments of Microbiology & Immunology, Epidemiology & Population Health, and Obstetrics, Gynecology & Women's Health, Albert Einstein College of Medicine, Bronx, NY.
Background: Gastric cancer (GC) is the fifth leading cause of cancer-related death worldwide. The oral microbiota was investigated for distinguishable characteristics between GC, premalignant gastric conditions (Pre-GC), and control participants.
Methods: Mouthwash samples from GC, Pre-GC, and control participants at a tertiary care center were prospectively collected.
Clin Oncol (R Coll Radiol)
October 2024
Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Aims: To evaluate outcomes and toxicity after intensity-modulated radiation therapy given as step-and-shoot (SS) or volumetric modulated arc therapy (VMAT) for patients with locally advanced esophageal cancer treated with trimodality therapy (i.e. neoadjuvant concurrent chemoradiation therapy followed by surgery).
View Article and Find Full Text PDFJ Neurosurg
December 2024
8Department of Surgery, Division of Neurosurgery, The University of Toronto, Ontario, Canada.
Blood Adv
December 2024
City of Hope, Duarte, California, United States.
The anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1) contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models.
View Article and Find Full Text PDFSci Adv
December 2024
Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.
Many viral proteins form biomolecular condensates via liquid-liquid phase separation (LLPS) to support viral replication and evade host antiviral responses, and thus, they are potential targets for designing antivirals. In the case of nonenveloped positive-sense RNA viruses, forming such condensates for viral replication is unclear and less understood. Human noroviruses (HuNoVs) are positive-sense RNA viruses that cause epidemic and sporadic gastroenteritis worldwide.
View Article and Find Full Text PDFLeuk Lymphoma
December 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The diagnosis of myeloid neoplasms with plasmacytoid dendritic cell (pDC) differentiation can be challenging due to immunophenotypic overlap requiring detailed characterization by flow cytometry and immunohistochemistry. We describe two patients with a history of myeloproliferative neoplasm (MPN) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) who presented years later with leukocytosis, lymphadenopathy, splenomegaly, and cachexia, with rapid clinical deterioration and death. Lymph node biopsy specimens revealed involvement by myeloid sarcoma with prominent pDC differentiation.
View Article and Find Full Text PDFCancer Cytopathol
January 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Genomic profiling is essential in the management of non-small cell lung cancer. However, this may often be challenging because of limited cytological tissue and extended turnaround time (TAT) for next-generation sequencing (NGS). This study aims to describe a rapid TAT workflow for molecular profiling using fine-needle aspiration (FNA) supernatants.
View Article and Find Full Text PDFDiagn Cytopathol
December 2024
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Extramedullary hematopoiesis (EMH) is usually seen in the reticuloendothelial system such as the spleen and liver; however, there have been rare case reports when EMH is seen in serous fluids (SFs). The aim of this study included analyzing the cytomorphological features of EMH in SFs in correlation with various clinicopathologic parameters and recognizing potential diagnostic pitfalls as well as their prognostic significance.
Methods: Clinicopathologic parameters and radiologic and pathologic information from the patients with a cytologic diagnosis of EMH were evaluated with cytology slides.
Oncologist
December 2024
Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Introduction: Patients with advanced cancer and their spousal caregivers who parent minor children report unmet parenting concerns and increased psychological distress. Seeking to address these important supportive care needs, this RCT examined the feasibility, acceptability, and initial evidence for the efficacy of a novel psychosocial intervention.
Patients And Methods: Patients with a metastatic solid malignancy and their spouses completed self-reported validated assessments of psychological symptoms and cancer-related parenting outcomes and were then randomized to the parent support intervention or a usual care (UC) group.
Technol Cancer Res Treat
December 2024
Department of Urology, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Clear cell renal cell carcinoma (ccRCC) is a highly lethal urinary malignancy with poor overall survival (OS) rates. Integrating computer vision and machine learning in pathomics analysis offers potential for enhancing classification, prognosis, and treatment strategies for ccRCC. This study aims to create a pathomics model to predict OS in ccRCC patients.
View Article and Find Full Text PDFPediatr Blood Cancer
December 2024
Division of Oncology, Children's National Hospital and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Purpose: National Wilms Tumor Study-5 (NWTS-5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT).
Patients And Methods: Eligible patients with RTK were enrolled prospectively on NWTS-5 (1995-2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005-2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH-1 or dose-reduced Revised UH-1).
Pediatr Blood Cancer
December 2024
Department of Pediatric Hematology/Oncology, Loma Linda University, Loma Linda, California, USA.